Mitralign, which is looking to commercialize its namesake mitral valve treatment and pursue regulatory nods for its Trialign tricuspid valve device, said it raised nearly $10 million. The $9.8 million funding, of a hoped-for $30.2 million, came from 19 unnamed investors beginning last September, the Tewksbury, Mass.-based company said in a regulatory filing. Mitralign raised […]
Mitralign said today it launched the Scout II study of its Trialign system designed for treating patients with tricuspid regurgitation, looking to support eventual CE Mark approval in the European Union. The Trialign device, which is designed to be delivered by catheter, uses implanted anchors to help restore valves to their natural shape and reduce tricuspid regurgitation, […]
Mitralign said today that it raised a Series E round worth nearly $40 million for a pair of heart valve repair devices, its namesake Mitralign annuloplasty system and the Trialign device for tricuspid repair. The Tewksbury, Mass.-based company said it plans to use some of the proceeds to pursue regulatory nods for the Trialign device in the […]
Mitralign said today that it won CE Mark approval in the European Union for its namesake device for treating functional mitral regurgitation. Tewksbury, Mass.-based Mitralign said the approval covers patients with symptomatic FMR. Its device, delivered via catheter, is designed to use anchors to help restore the heart’s mitral valve to its natural shape. The company said […]
Mitralign said today that it enrolled the 1st patient in the Scout feasibility trial of its Trialign tricuspid valve repair device under an investigational device exemption. The Tewksbury, Mass.-based company’s Trialign device is designed to use wire and catheters to implant polyester anchors within the annulus of the tricuspid valve, which separates the heart’s right atrium and right ventricle. The anchors […]
The European Society of Cardiology Congress conference wrapped up this week in London. Here’s a roundup of news from the overseas meeting of interventional cardiologists, dominated by data on fractional flow reserve technology. FFR: St. Jude touts 5 year data showing long-term benefits St. Jude Medical (NYSE:STJ) released 5-year data from a trial comparing the use […]
Mitralign said today that the FDA approved a U.S. feasibility study of its tricuspid valve repair device, under an investigational device exemption. Tewksbury, Mass.-based Mitralign did not provide any details on the Scout study or its design for its percutaneous tricuspid valve annuloplasty device, other than that it will occur at “select” sites in the […]
June 24, 2014 by Arezu Sarvestani
Mitralign added more than $8 million to its coffers in an equity funding round, after closing enrollment of a clinical trial for its namesake mitral valve repair device in April.
The Mitralign system is designed to deliver via catheter at least 1 pair of anchors that, when cinched together, help restore the heart’s mitral valve to its natural shape in patients with functional mitral regurgitation, according to a press release.
The New York Stock Exchange was closed for a 2nd day today for the 1st time in 124 years, after Hurricane Sandy had its way with lower Manhattan yesterday. The storm also took out the NASDAQ exchange.
The Category I hurricane killed at least 108 people as is raged up the Eastern Seaboard from the Caribbean, 39 of them in the U.S.
The NYSE and NASDAQ said they plan to re-open tomorrow.